Skip to main content
OpenTrials
Completed

NCT Number: NCT03612544

The ESTxENDS Trial- Substudy on the Effect on Toxins From Using Electronic Nicotine Delivery Systems (ENDS/Vaporizer/E-cig)

--> This is a substudy of the main ESTxENDS trial (NCT03589989). Toxins outcomes should be considered secondary outcomes of the main smoking cessation outcome formulated in NCT03589989.

Cigarette smoking is the leading cause of preventable death in Switzerland. Recently, electronic nicotine delivery systems (ENDS; also called vaporizer or electronic cigarette) have become popular with smokers who want to stop smoking or reduce their exposure to inhaled chemicals since ENDS use appears to be safer than tobacco smoking.

Conventional cigarettes release toxic chemicals in tobacco smoke through thermochemical degradation and pyrolysis processes by combusting tobacco, but in ENDS toxicants can be released by heating up nicotine-containing e-liquids to produce vapor. The e-liquid in ENDS is mostly made of propylene glycol (PG) and vegetal glycerin (VG) in addition to nicotine, flavorings and sometimes alcohol as a conservation agent. The heating process of the e-liquid in ENDS, has been shown to release carcinogens such as some carbonyl and volatile organic compounds (i.e., formaldehyde, acetaldehyde and acrolein). Some devices might also release heavy metals such as cadmium, lead and mercury. The source of such metals may be the metal of the device or the e-liquids. Although unexpected from the composition of the e-liquids, some studies have also detected tobacco-specific nitrosamines (TNSAs) (N'-nitrosonornicotine (NNN) and 4-(methylnitrosoamino)-1-(3-pyridyl)-1-butanone (NNK)) and polycyclic aromatic hydrocarbons (PAHs) (1- and 2-Naphtol and 1-hydroxypyrene (1-OHP)).

This study will therefore test the efficacy of ENDS for cigarette smoking cessation, the safety of ENDS on adverse events and the effect of ENDS on health-related outcomes and exposure to inhaled chemicals.

For the main ESTxENDS trial (NCT03589989), cigarette smokers motivated to quit smoking cigarettes will be included. Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants in the control group will receive smoking cessation counseling only. All participants will be followed over a 24-month period. Chemicals such as VOCs, PAHs, TSNAs, heavy metals, nicotine and nicotine degradation products will first be quantified in the aerosol produced by ENDS in laboratory conditions. These chemicals and their metabolites will then be measured at baseline and at 6-, 12- and 24- months' follow-up in urine samples from study participants.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Unisanté, Centre universitaire de médecine générale et santé publique, Université de Lausanne, Lausanne, Canton of Vaud, Switzerland

Loading trial locations.

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Informed Consent as documented by signature
  • Persons aged 18 or older
  • Currently smoking 5 or more cigarettes a day for at least 12 months
  • Willing to try to quit smoking within the next 3 months,
  • Persons providing a valid phone number, a valid email address and/or a valid postal address.

Exclusion criteria

  • Known hypersensitivity or allergy to contents of the e-liquid
  • Participation in another study with investigational drug within the 30 days preceding the baseline visit and during the present study where interactions are to be expected
  • Women who are pregnant or breast feeding
  • Intention to become pregnant during the course of the scheduled study intervention, i.e. within the first 6-months of the study
  • Persons having used ENDS or tobacco heating systems regularly in the 3 months preceding the baseline visit
  • Persons having used nicotine replacement therapy (NRT) or other medications with demonstrated efficacy as an aid for smoking cessation such as varenicline or bupropion within the 3 months preceding the baseline visit
  • Persons who cannot attend the 6- month follow-up visit for any reason
  • Cannot understand instructions delivered in person or by phone, or otherwise unable to participate in study procedures

Treatment and study plan

ENDS (vaporizer/e-cig) and smoking cessation counseling

Other

Participants in the intervention group will receive an ENDS and nicotine-containing e-liquids, which they will be allowed to use ad libitum. Additionally, they will receive smoking cessation counseling. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Smoking cessation counseling

Other

Participants in the control group will receive smoking cessation counseling only. Participants will be allowed to additionally use nicotine replacement therapy. All participants will be followed over a 24-month period. Smoking cessation counseling will be provided in person at the first clinical visit and then over the phone at the target quit date one week later and again at week 2, 4 and 8 after the target quit date. After 6, 12 and 24 months, participants will be asked to come to a clinical visit.

Primary outcomes

  1. Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_1

    Time frame: 6 months post quit date

    Measurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine

  2. Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_2

    Time frame: 12 months post quit date

    Measurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine

  3. Concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)_3

    Time frame: 24 months post quit date

    Measurement of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) in urine

  4. Concentrations of urinary NNN (N-nitrosonornicotine)_1

    Time frame: 6 months post quit date

    Measurement of NNN (N-nitrosonornicotine) in urine

  5. Concentrations of urinary NNN (N-nitrosonornicotine)_2

    Time frame: 12 months post quit date

    Measurement of NNN (N-nitrosonornicotine) in urine

  6. Concentrations of urinary NNN (N-nitrosonornicotine)_3

    Time frame: 24 months post quit date

    Measurement of NNN (N-nitrosonornicotine) in urine

  7. Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_1

    Time frame: 6 months post quit date

    Measurement of NNK (nicotine-derived nitrosamine ketone) in urine

  8. Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_2

    Time frame: 12 months post quit date

    Measurement of NNK (nicotine-derived nitrosamine ketone) in urine

  9. Concentrations of urinary NNK (nicotine-derived nitrosamine ketone)_3

    Time frame: 24 months post quit date

    Measurement of NNK (nicotine-derived nitrosamine ketone) in urine

  10. Concentrations of urinary metabolites of VOCs (volatile organic compounds)_1

    Time frame: 6 months post quit date

    Measurements of metabolites of VOCs in urine

  11. Concentrations of urinary metabolites of VOCs (volatile organic compounds)_2

    Time frame: 12 months post quit date

    Measurements of metabolites of VOCs in urine

  12. Concentrations of urinary metabolites of VOCs (volatile organic compounds)_3

    Time frame: 24 months post quit date

    Measurements of metabolites of VOCs in urine

  13. Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_1

    Time frame: 6 months post quit date

    Measurement of PAHs (Polycyclic aromatic hydrocarbons) in urine

  14. Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_2

    Time frame: 12 months post quit date

    Measurement of PAHs (Polycyclic aromatic hydrocarbons) in urine

  15. Concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)_3

    Time frame: 24 months post quit date

    Measurement of PAHs (Polycyclic aromatic hydrocarbons) in urine

  16. Concentrations of urinary heavy metals_1

    Time frame: 6 months post quit date

    Measurement of heavy metals in urine

  17. Concentrations of urinary heavy metals_2

    Time frame: 12 months post quit date

    Measurement of heavy metals in urine

  18. Concentrations of urinary heavy metals_3

    Time frame: 24 months post quit date

    Measurement of heavy metals in urine

  19. Concentrations of urinary nicotine metabolites_1

    Time frame: 6 months post quit date

    Measurement of nicotine metabolites in urine

  20. Concentrations of urinary nicotine metabolites_2

    Time frame: 12 months post quit date

    Measurement of nicotine metabolites in urine

  21. Concentrations of urinary nicotine metabolites_3

    Time frame: 24 months post quit date

    Measurement of nicotine metabolites in urine

Secondary outcomes

  1. Change in concentrations of urinary NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol)

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of NNAL (4-(Methylnitrosamino)-1-(3-pyridyl)-1-butanol) concentrations in urine from baseline to 6, 12, and 24 months post quit date.

  2. Change in concentrations of urinary NNN (N-nitrosonornicotine)

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of NNN (N-nitrosonornicotine) concentrations in urine from baseline to 6, 12, and 24 months post quit date.

  3. Change in concentrations of urinary NNK (nicotine-derived nitrosamine ketone)

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of NNK (nicotine-derived nitrosamine ketone) concentrations in urine from baseline to 6, 12, and 24 months post quit date.

  4. Change in concentrations of urinary VOCs (volatile organic compounds)

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of VOCs (volatile organic compounds) concentrations in urine from baseline to 6, 12, and 24 months post quit date.

  5. Change in concentrations of urinary PAHs (Polycyclic aromatic hydrocarbons)

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of PAHs (Polycyclic aromatic hydrocarbons) concentrations in urine from baseline to 6, 12, and 24 months post quit date.

  6. Change in concentrations of urinary heavy metals

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of heavy metals concentrations in urine from baseline to 6, 12, and 24 months post quit date.

  7. Change in concentrations of urinary nicotine metabolites

    Time frame: Change from baseline to 6,12, 24 months post quit date

    Change of nicotine metabolites concentrations in urine from baseline to 6, 12, and 24 months post quit date.

Sponsors and collaborators

Lead sponsor

University of Bern

Other

Collaborators

  • Federal Office of Public Health, Switzerland
  • Krebsforschung Schweiz, Bern, Switzerland
  • State Hospital, St. Gallen
  • Swiss National Science Foundation
  • University of Geneva, Switzerland
  • University of Lausanne
  • University of Zurich

Registry information

Official study title

Substudy of Efficacy, Safety and Toxicology of Electronic Nicotine Delivery Systems as an Aid for Smoking Cessation (ESTxENDS Trial)- the Toxins Substudy of ESTxENDS

Acronym: ESTxENDS

Important dates

Study start
2018
Primary completion
2023
Study completion
2023
First posted
Aug 2, 2018
Registry last updated
Nov 15, 2023

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.